TrialAnnals of the rheumatic diseases2022

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).

Laura C Coates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.